mobile
Life Science Conclave 2011:"Enabling Growth through collaborative R&D and Technology Transfer"
HighLights
 

a)      Dr. Nata Menabde, WHO representative designate to India, said that just as in China there was a skew between the economic leg and the social leg, there is a skew between private healthcare and public healthcare system in India. She also  emphasised the need for a new era of public-private collaborations in R&D.

 

b)      Dr. Y K Gupta, professor and head pharmacology, AIIMS spoke on the issue of affordability and availability of essential medicines and rued the fact that the growth of clinical research in the country had plateaued. He also said “Quality of data produced during such research projects should be our focus rather than the cost of the project,”

 

c)     Mr. Satish Reddy, chairman CII National Committee on Drugs and Pharmaceuticals and Managing Director and Chief Operating Officer, Dr. Reddy's Laboratories said, “Indian firms produce about 60,000 generic brands across 60 therapeutic categories. India is also among the world’ leading five producers of active pharmaceutical ingredients (API), while in formulations India is the second largest producer in the world.” Some of the world’s least expensive drugs are produced in India due to 50-55 per cent lower labour costs than in the West.”

 

d)       Dr. Rajesh Jain, chairman CII National Committee on Biotechnology and joint managing director, Panacea Biotec moderated and concluded the inaugural session with his novel suggestions on tax reforms in R&D. Jain advocated the long term incentivisation of R&D and mentioned that short term fiscal incentives do not encourage the industry to invest on long term R&D projects. He also recommended the inclusion of outhouse clinical trials for weighted tax exemption and waiving off sales tax and excise on all paediatric products.

 
Description

Research and development is becoming increasingly open and globally-connected activities. The linear model of basic research leading to applied research, that supports development followed by market application, is no longer an accurate reflection of what is happening, in the face of growing (scientific, technical and business) complexity and the requirements for rapid speed to market in global competition. A more strategic approach to collaboration and stronger management of knowledge exchange are seen as being integral to the effectiveness of these research and development activities.

Objective of the Conclave was to :

1-     To provide a forum to present and discuss the role of key stakeholders towards realizing India’s potential in collaborative R&D and making it a hub of Life Science Innovation.

2-     To deliberate on various practices for promoting collaboration between academia, industry and health care professionals.

3-     To provide a glimpse into two potential areas of focus and opportunity – Technology Commercialization and collaborative Innovation.

4-     To discuss current state and capability building in different areas like Safe Medicine, IPR in Life Sciences, Industry-Academia Partnership and Regulatory Practices through scientific sessions.

5-     To deliberate on Govt. of India’s mission on research and innovation in life sciences via technology disposition by various govt. organizations in association with Indian Industry.

 The Conclave had following sessions covering:

a)     Trend in R&D and Technology Transfer

b)    Safe Medicine-Requirements and Availability

c)     Augmentation of Global Industry and Academia Partnership

d)    Federal Initiatives and Venture funding- Entrepreneurial Opportunities for Life Sciences Sector

e)     Intellectual Property: Generation, Protection and Enforcement.

f)     CTO/ CSO Conference : An Integrated Platform for Technology and Research Disposition

 

Pharma Secure, Dr. Reddy’s Laboratories and Fresenius Kabi where the sponsors of the Summit

Sponsored By
Knowledge Resources
You will get access to following Knowledge Resources by subscribing to the Digital Library of this event.
 
Inaugural Session:1 - Welcome Address & Moderated by Mr Rajesh Jain, Chairman, CII National Committee on Biotechnology, Joint Managing Director, Panacea Biotec Ltd.
Inaugural Session:2 - Address by Mr Nata Menabde, WHO Representative Designate to India
Inaugural Session:3 - Address by Mr Satish Reddy, Chairman, CII National Committee on Drugs & Pharmaceuticals, MD & COO, Dr. Reddy’s Laboratories Ltd.
Inaugural Session:4 - Address by Mr Y K Gupta, Head- Pharmacology, All India Institute of Medical Sciences
Inaugural Session:5 - Address by Mr Steven T Smith, Health Attaché, Embassy of USA, New Delhi
Inaugural Session:6 - Release of Compendiums
Inaugural Session:7 - Concluding Remarks by the Moderator Mr Rajesh Jain, Chairman, CII National Committee on Biotechnology, Joint Managing Director, Panacea Biotec Ltd & close of Session
Session 1:1 - Moderator by Mr H K Mittal, Secretary, Technology Development Board, Ministry of Science and Technology
Session 1:2 - Mr V K Vinayak, Chief Scientific Officer, Panacea Biotec Ltd.
Session 1:3 - Mr Bakulesh M Khamar, Executive Director-Research, Cadila Pharmaceuticals Ltd.
Session 1:4 - Mr Sundeep Kumar, Head-Corporate Affairs, Novartis India Ltd.
Session 1:5 - Mr Arunabha Pradhan, Chief, Business Operations & Development, National Research Development Corporation
Session 1:6 - Mr Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
Session 2:1 - Moderator Mr Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
Session 2:2 - Mr Rajinder K Jalali, Vice President Medical Affairs & Clinical Research and Head – Global Pharmacovigilance, Ranbaxy Laboratories Ltd.
Session 2:3 - Mr Tom Woods, President, Woods International, LLC
Session 2:4 - Mr Tobby Simon, President, The Synergia Foundation - Knowledge Beyond Borders
Session 2:5 - Mr Premnath Shenoy, Director- Regulatory Affairs AstraZeneca Pharma India Ltd.
Session 2:6 - Discussion of Session II : Safe Medicine-Requirements & Availability
Session 3:1 - Moderator - Mr Harsh Manglik, Senior Advisor, Accenture
Session 3:2 - Mr. Raman Govindarajan, Head India R&D, Sanofi Aventis Ltd.
Session 3:3 - Mr. Balu Chopade, Director, Institute of Bioengineering & Bioinformatics, University of Pune
Session 3:4 - Mrs. Malathi Lakshmi Kumaran, Consultant, Lakshmi Kumaran & Sridharan
Session 3:5 - Mrs. S N Khan, Scientist- F, Department of Science & Technology, Ministry of Science and Technology
Session 3:6 - Question & Answer
Session 4:1 - Moderator, Mr. R K Das, General Manager, SIDBI
Session 4:2 - Mr. Michael Ryan, Georgetown University Business School, Washington, DC
Session 4:3 - Mr. Prashanta Banerjee, Industrial Engineering, Bioengineering, Computer Science and Ophthalmology & Visual Science, University of Illinois
Session 4:4 - Mr. Jay Kesan, Professor and Director of IP Law, University of Illinois at Urbana
Session 4:5 - Mr. Shailendra Tandon, Cheif Finacial Officer, Asian Healthcare fund
Session 4:6 - Mr. Vishal Gandhi, VP & Head Life Science Banking, Yes Bank Ltd.
Session 5:1 - Moderator, Mr. Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
Session 5:2 - Mr. Janet McNicholas, K & L Gates, LLP, Chicago & Palo Alto
Session 5:3 - Ms. Rachal Winger, K & L Gates, LLP, Seattle
Session 5:4 - Ms. Malathi Lakshmi Kumaran, Consultant, Lakshmi Kumaran & Sridharan
Session 5:5 - Mr. Ananda Mohan Chakrabarty, Distinguished University Professor, Department of Microbiology and Immunology, University of Illinois, Chicago
Session 5:6 - Mr. Pravin Anand, Managing Partner, Anand And Anand
Session 6:1 - Session Moderator, Mr V M Katoch, Director General, ICMR & Secretary, Health Services, Ministry of Health and Family Welfare
Session 6:2 - Mr Raman Govindarajan, Head India R&D, Sanofi Aventis Ltd.
Session 6:3 - Mr T K Chakraborty, Director, Central Drug Research Institute
Session 6:4 - Mr Arunabha Pradhan, Chief, Business Operations & Development, National Research Development Corporation
Session 6:5 - Ms. Monika Verma, Director, Dept of Pharmaceuticals, Ministry of Chemicals and Fertilizers
Session 6:6 - Dr. Syeda Saiyidain Hameed, Member Planning
Session 6:7 - Mr. R Ram A Vishwakarma, Director, Indian Institute of Integrative Medicine (IIIM)
Session 6:8 - Ms. Soumya Swaminathan, Director in-charge, National institute for research in tuberculosis
Session 6:9 - Ms. Jyoti Yadav, Head- PME, Institute of Genomics & Integrative Biology (IGIB)
Session 6:9a - Ms. Brinda K Varma, Innovation Centre, Indian Institute of Science
Session 6:9b - Mr. Ketan Divang,Mr. Ketan Divang addressing at the Session VI- CTO/CSO Conference
Session 6:9c - Concluding Remarks at the Session VI- CTO/CSO Conference
 
Charges to access Event
 
Participant TypeAmount (in Rs)
Member
0
NonMember
0